Ulisse Biomed S.p.A. and Ikonisys SA, a company specialising in the early and accurate diagnosis of cancer through a unique and fully automated solution for medical analysis laboratories, announce a strategic collaboration to enhance their technical and commercial capabilities in oncology diagnostics.
A key aspect of this collaboration is the integration of UBM's expertise in Molecular Biology with Ikonisys' Liquid Cytology (LBC) and Fluorescence In Situ Hybridization (FISH) technology. This integration is intended to provide innovative oncology diagnostics, offering comprehensive and accurate diagnostic capabilities that can significantly improve patient outcomes. As part of this partnership:
- Companies will explore cross-selling and co-marketing opportunities through their sales networks to maximise market penetration and exploit product and service synergies. In a second phase, a mutual distribution agreement will be defined.
- Ikonisys and UBM are committed to working together to explore and develop new business opportunities. This partnership reflects the shared goal to innovate and grow by combining skills and resources. Technical discussions will also be conducted to discuss potential manufacturing and OEM agreements, with the aim of optimising production techniques and ensuring high product quality. The initiative will integrate the technical expertise of both companies, promoting innovative and competitive solutions in oncology diagnostics.
The partnership will first take place with the mutual installation and training of instruments at Hospitex Lab in Florence, part of the IKONISYS Group, scheduled for late June to mid-July. Thanks to this cooperation, the companies will be able to familiarise themselves with each other's technologies and skills, fostering closer technical cooperation.
In autumn 2024, Ikonisys and UBM will jointly organise a demonstration day to show their technologies and products to customers. This event will be an opportunity to assess the added value of their cooperation, allowing direct interaction with customers, gathering feedback and thus identifying market opportunities.
Mario Crovetto, CEO of Ikonisys, added: "UBM's innovative technology and vision are perfectly aligned with Ikonisys' development strategy, particularly with the recent integration of Hyris. Following the announcement of the integration of Hospitex on our side, which is still ongoing, this partnership attests to our relentless commitment to further maximising value for our shareholders and delivering integrated and accurate diagnostic solutions to our customers. By joining forces with UBM, we are able to accelerate our growth strategy by further expanding our core business and expanding our sales network.
Nicola Basile, Managing Director of Ulisse Biomed, said: 'We consider Ikonisys a partner with many strategic points for the UBM Group, from the technological point of view to the commercial synergy. We anticipate a great collaboration in the future. In recent months we have been working on our integration with Hyris and this partnership confirms that we are on the right track to be a relevant player in the market with meaningful solutions for customers and prospects".
